COR-1004 vs Ebronucimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
COR-1004
Developed by Corsera Health
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07229118 (registry estimate)
No aligned efficacy figure on record for this race.
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | COR-1004 | Ebronucimab |
|---|---|---|
| LDL-C, % change | —Not reported | —Not posted · NCT05260411 |
| Non-HDL-C, % change | —Not reported | —Not posted · NCT05260411 |
| ApoB, % change | —Not reported | —Not posted · NCT05260411 |
| Lp(a), % change | —Not reported | —Not posted · NCT05260411 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05260411 |
LDL-C, % change
- COR-1004
- —Not reported
- Ebronucimab
- —Not posted · NCT05260411
Non-HDL-C, % change
- COR-1004
- —Not reported
- Ebronucimab
- —Not posted · NCT05260411
ApoB, % change
- COR-1004
- —Not reported
- Ebronucimab
- —Not posted · NCT05260411
Lp(a), % change
- COR-1004
- —Not reported
- Ebronucimab
- —Not posted · NCT05260411
3-point MACE (% with event)
- COR-1004
- —Not reported
- Ebronucimab
- —Not posted · NCT05260411
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
COR-1004: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ebronucimab
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: COR-1004's landscape · Ebronucimab's landscape